Entrada Therapeutics, Inc. (TRDA)
NASDAQ: TRDA · Real-Time Price · USD
6.63
-0.07 (-1.04%)
At close: May 27, 2026, 4:00 PM EDT
6.76
+0.13 (1.96%)
After-hours: May 27, 2026, 6:46 PM EDT
Entrada Therapeutics Market Cap
Entrada Therapeutics has a market cap or net worth of $238.9 million as of May 27, 2026. Its market cap has decreased by -19.14% in one year.
Market Cap
238.90M
Enterprise Value
33.79M
1-Year Change
-19.14%
Ranking
Category
Stock Price
$6.63
Market Cap Chart
Since the IPO on October 29, 2021, Entrada Therapeutics's market cap has decreased from $251.01M to $238.90M, a decrease of -4.82%. That is a compound annual growth rate of -1.08%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| May 26, 2026 | 241.42M | -34.51% |
| Dec 31, 2025 | 368.66M | -39.78% |
| Dec 31, 2024 | 612.16M | 21.70% |
| Dec 29, 2023 | 503.01M | 18.72% |
| Dec 30, 2022 | 423.70M | -20.71% |
| Dec 31, 2021 | 534.36M | 112.88% |
| Oct 29, 2021 | 251.01M | - |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Anavex Life Sciences | 247.90M |
| Sol-Gel Technologies | 245.17M |
| Adagene | 245.13M |
| LENZ Therapeutics | 243.78M |
| Minerva Neurosciences | 243.19M |
| Humacyte | 243.11M |
| Alector | 241.48M |
| Context Therapeutics | 238.89M |